Vertistop® D and Vertistop® L in Preventing Recurrence of High-recurrence BPPV

Benign Paroxysmal Positional Vertigo (BPPV) Clinical Trial

Official title: Randomized, 3-arm Controlled Clinical Trial, Designed to Evaluate the Effectiveness of Supplementation With Vertistop® D and Vertistop® L in Preventing Recurrence of High-recurrence BPPV (Benign Paroxysmal Positional Vertigo)

Status Completed

Clinical Trial Summary

Randomized, 3-arm controlled clinical study, to evaluate the effectiveness of supplementation with Vertistop® D (food supplement containing alpha-lipoic acid at modified release, Carnosine and Zinc, Vitamin D and Vitamins B) and Vertistop® L (food supplement containing fast releasing alpha-lipoic acid, Carnosine, Zinc and Curcumin) in preventing recurrence of high-recurrence BPPV (Benign Paroxysmal Positional Vertigo)

Clinical Trial Description

Benign paroxysmal positional vertigo (BPPV) is the most common type of vertigo detectable in otoneurological clinical practice. It is characterized by violent, short and relapsing vertiginous crises that arise when the patient assumes certain positions of the head in the space and is accompanied by a usually "typical" paroxysmal positional nystagmus. In most cases we cannot trace the exact causal agent, so we mainly identify two forms: primitive forms and secondary forms. BPPV therapy is essentially physical, and it is based on specific maneuvers which make the otoconial mass come out of the semicircular canal. Recent studies showed the existence of a seasonal trend of BPPV related to fluctuations in Vitamin D levels. Based on these considerations this clinical trial was designed in order to evaluate the possible efficacy of the administration of Vitamin D (Vertistop® D) in preventing recurrence of BPPV. ;

Related Conditions & MeSH terms

• Benign Paroxysmal Positional Vertigo
• Benign Paroxysmal Positional Vertigo (BPPV)
• Dizziness
• Recurrence
• Vertigo

• NCT number: NCT04849182
• Study type: Interventional
• Source: Azienda Sanitaria Locale di Matera
• Status: Completed
• Phase: N/A
• Start date: December 4, 2018
• Completion date: November 3, 2020